|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.16 USD | -7.14% |
|
+16.45% | +65.17% |
| 06:00pm | The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause? |  |
| 01:24pm | Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna… | |
| Capitalization | 20.27B 17.25B 16.02B 15.02B 27.97B 1,856B 29.65B 183B 72.48B 877B 76B 74.44B 3,209B | P/E ratio 2025 * |
-6.49x | P/E ratio 2026 * | -7.49x |
|---|---|---|---|---|---|
| Enterprise value | 14.97B 12.74B 11.83B 11.09B 20.66B 1,371B 21.9B 135B 53.53B 648B 56.13B 54.98B 2,370B | EV / Sales 2025 * |
8.02x | EV / Sales 2026 * | 8.53x |
| Free-Float |
90.48% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | -7.04% | ||
| 1 week | +16.45% | ||
| Current month | +65.17% | ||
| 1 month | +50.85% | ||
| 3 months | +85.56% | ||
| 6 months | +40.50% | ||
| Current year | +65.17% |
| 1 week | 40.7 |  | 55.2 |
| 1 month | 29.06 | | 55.2 |
| Current year | 29.81 | | 55.2 |
| 1 year | 22.28 | | 55.2 |
| 3 years | 22.28 | | 197.06 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 53 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 06/09/2022 |
Stephen Hoge
PSD | President | 50 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 67 | 01/06/2018 |
Noubar Afeyan
CHM | Chairman | 62 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 53 | 01/03/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.14% | +16.45% | +14.91% | -75.27% | 20.27B | |
| -0.50% | +2.78% | +8.46% | +3.22% | 77.51B | |
| +1.35% | +80.20% | +80.20% | +80.20% | 56.2B | |
| +0.68% | +2.48% | -33.54% | -39.93% | 58.79B | |
| -0.58% | -3.09% | +40.04% | +234.20% | 57.8B | |
| -1.31% | +4.57% | +19.67% | -41.11% | 25.5B | |
| -3.79% | -4.35% | +40.07% | +21.69% | 20.63B | |
| +2.83% | -5.96% | +162.38% | +94.20% | 18.11B | |
| -1.93% | +3.36% | +112.51% | +825.12% | 15.4B | |
| -0.04% | -.--% | +3.71% | +175.02% | 14.02B | |
| Average | -1.03% | +2.82% | +44.84% | +127.73% | 36.42B | |
| Weighted average by Cap. | -0.52% | +1.44% | +32.56% | +84.25% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.87B 1.59B 1.48B 1.38B 2.58B 171B 2.73B 16.85B 6.68B 80.77B 7B 6.86B 296B | 2.01B 1.71B 1.59B 1.49B 2.77B 184B 2.94B 18.11B 7.17B 86.81B 7.52B 7.37B 318B |
| Net income | -3.07B -2.61B -2.43B -2.27B -4.24B -281B -4.49B -27.7B -10.98B -133B -11.51B -11.27B -486B | -2.71B -2.31B -2.14B -2.01B -3.74B -248B -3.96B -24.45B -9.69B -117B -10.16B -9.95B -429B |
| Net Debt | -5.3B -4.51B -4.19B -3.93B -7.31B -485B -7.75B -47.83B -18.95B -229B -19.87B -19.47B -839B | -3.15B -2.68B -2.49B -2.34B -4.35B -289B -4.61B -28.45B -11.28B -136B -11.82B -11.58B -499B |
More financial data
* Estimated data
Employees
5,800
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 48.68 $ | -6.15% | 9,911,148 |
| 22/01/26 | 51.87 $ | +4.14% | 34,243,466 |
| 21/01/26 | 49.81 $ | +15.84% | 22,612,253 |
| 20/01/26 | 43.00 $ | +2.80% | 12,604,324 |
| 16/01/26 | 41.83 $ | +6.28% | 11,891,053 |
Delayed Quote Nasdaq, January 23, 2026 at 08:39 pm
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
51.87USD
Average target price
37.40USD
Spread / Average Target
-27.90%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition